



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/009,383	03/04/2002	Maria Laura Gennaro	07763-043001 7070	
26211 7	590 11/17/2005		EXAMINER	
FISH & RICHARDSON P.C. P.O. BOX 1022			SWARTZ, RODNEY P	
MINNEAPOLIS, MN 55440-1022			ART UNIT	PAPER NUMBER
			1645	

DATE MAILED: 11/17/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/009,383	GENNARO, MARIA LAURA		
Examiner	Art Unit		
Rodney P. Swartz, Ph.D.	1645		

	Rodney P. Swartz, Ph.D.	1645					
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence add	ress				
THE REPLY FILED 24 January 2005 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.							
1. The reply was filed after a final rejection, but prior to or on this application, applicant must timely file one of the follow places the application in condition for allowance; (2) a No a Request for Continued Examination (RCE) in compliance time periods:	the same day as filing a Notice of wing replies: (1) an amendment, affitice of Appeal (with appeal fee) in c	Appeal. To avoid aba idavit, or other evider compliance with 37 C	nce, which FR 41.31; or (3)				
a) The period for reply expiresmonths from the mailing b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire be Examiner Note: If box 1 is checked, check either box (a) or (b)	dvisory Action, or (2) the date set forth ater than SIX MONTHS from the mailing	date of the final rejecti	on.				
TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, nay reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
NOTICE OF APPEAL 2. The Notice of Appeal was filed on 23 August 2004. A brid the date of filing the Notice of Appeal (37 CFR 41.37(a)), appeal. Since a Notice of Appeal has been filed, any reply AMENDMENTS	or any extension thereof (37 CFR 4	1.37(e)), to avoid dis	missal of the				
3. The proposed amendment(s) filed after a final rejection,	but prior to the date of filing a brief.	will not be entered b	ecause				
(a) They raise new issues that would require further co							
(b) They raise the issue of new matter (see NOTE belo	· ·						
(c) They are not deemed to place the application in bet	tter form for appeal by materially re	ducing or simplifying	the issues for				
appeal; and/or (d) ☐ They present additional claims without canceling a	corresponding number of finally rei	ected claims.					
NOTE: (See 37 CFR 1.116 and 41.33(a)).	-						
4. The amendments are not in compliance with 37 CFR 1.1		mpliant Amendment	(PTOL-324).				
5. ี Applicant's reply has overcome the following rejection(s)	: none, see attached Detailed Action	<u>on</u> .					
6. Newly proposed or amended claim(s) would be a	llowable if submitted in a separate,	timely filed amendme	ent canceling the				
non-allowable claim(s). 7. For purposes of appeal, the proposed amendment(s): a)	☐ will not be entered or b\ ☒ wil	I he entered and an	evolunation of				
how the new or amended claims would be rejected is pro The status of the claim(s) is (or will be) as follows:		i be entered and an	explanation of				
Claim(s) allowed:							
Claim(s) objected to: Claim(s) rejected: <u>1-18,35-54</u> .							
Claim(s) withdrawn from consideration:							
AFFIDAVIT OR OTHER EVIDENCE							
8. The affidavit or other evidence filed after a final action, bubecause applicant failed to provide a showing of good an was not earlier presented. See 37 CFR 1.116(e).							
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to showing a good and sufficient reasons why it is necessar	overcome <u>all</u> rejections under appea	al and/or appellant fa	ils to provide a				
10. The affidavit or other evidence is entered. An explanation	n of the status of the claims after e	ntry is below or attac	ned.				
REQUEST FOR RECONSIDERATION/OTHER 11. The request for reconsideration has been considered bu	it does NOT place the application in	n condition for allowa	nce because:				
12. Note the attached Information Disclosure Statement(s). (PTO/SB/08 or PTO-1449) Paper No(s).							
13. Other:							

Application/Control Number: 10/009,383

Art Unit: 1645

DETAILED ACTION

1. Applicant's Response to Advisory Action, received 24 January 2005, is acknowledged. Claims 1, 11, and 35 have been amended.

2. Claims 1-18 and 35-54 are pending and under consideration.

Rejections Maintained

3. The rejection of claims 1-18 and 35 under 35 U.S.C. 112, first paragraph, scope of enablement for polypeptides other than MTBN4, is maintained for reasons of record.

Applicant argues that in view of the data in the specification and the knowledge and skill of those in the art, such artisans would believe it likely that these additional polypeptides would, like MTBN4, have *M. tuberculosis* specific antigenic properties. Applicant indicates that the specificity analysis described in Brusasca et al (*Scand. J. Immunol.*, <u>54</u>:448-452, 2001) support applicant's argument, i.e., subjects infected with *M. tuberculosis* contain antibodies that bind MTBN1, MTBN2, MTBN4, MTBN7, and ESAT-6. However, subjects infected with other *Mycobacteria* as well as "normal" subjects had no antibodies to these polypeptides.

The examiner has considered applicant's arguments, but does not find them persuasive. Brusasca et al, Table 1, assessed the antibody responses to RD1 antigens in 3 groups of human subjects. Group 1, 75 patients, had active pulmonary TB. Group 2, 16 patients, had nonidentified non-TB mycobacterioses. Group 3, 50 controls, were healthy. It is difficult to determine whether the listed RD1 antigens are specific for *M. tuberculosis* because the identity of the MOTT bacteria are not identified. For instance, are the MOTT patients all infected with **only one** mycobacteria or with 16 different mycobacteria? At the present time, the specificity issue remains in question. Thus, while one of skill in the art may believe that some specificity may exist, the data in the instant specification and that in Bruscasca et al do not support the

Art Unit: 1645

scope of the instant claims. In addition, the embodiment in the claims of "a second amino acid sequence identical to said first amino acid sequence but with conservative substitutions" has lacks support for indicating which substitutions are allowable without removal of applicant's claim of *M. tuberculosis* specificity.

4. The rejection of claims 36-54 under 35 U.S.C. 112, second paragraph, indefiniteness, is maintained for reasons of record.

Conclusion

- 5. No claims are allowed.
- 6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Rodney P. Swartz, Ph.D., Art Unit 1645, whose telephone number is (571) 272-0865. The examiner can normally be reached on Monday through Thursday from 5:30 AM to 4:00 PM EST.

If attempts to reach the Examiner by telephone are unsuccessful, the examiner's supervisor, Lynette F. Smith, can be reached on (571)272-0864.

The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Application/Control Number: 10/009,383

Art Unit: 1645

Page 4

RODNEY P SWARTZ, PH. PRIMARY EXAMINER Art Unit 1645

November 15, 2005